Chemoinformaics analysis of (E)-3-Hydroxyfarnesa-1,6,10-trien-9-yl 2-methylbutyrate
Molecular Weight | 322.489 | nRot | 10 |
Heavy Atom Molecular Weight | 288.217 | nRig | 4 |
Exact Molecular Weight | 322.251 | nRing | 0 |
Solubility: LogS | -4.12 | nHRing | 0 |
Solubility: LogP | 4.413 | No. of Aliphatic Rings | 0 |
Acid Count | 0 | No. of Aromatic Rings | 0 |
Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
Atoms Count | 57 | No. of Aliphatic Hetero Cycles | 0 |
No. of Heavy Atom | 23 | No. of Aromatic Carbocycles | 0 |
nHetero | 3 | No. of Aromatic Hetero Cycles | 0 |
nBridge Head | 0 | No. Saturated Carbocycles | 0 |
No. of Hydrogen atom | 34 | No. of Saturated Hetero Cycles | 0 |
No. of Carbon atom | 20 | No. of Saturated Rings | 0 |
No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
No. of Oxygen atom | 3 | No. of Arom Bond | 0 |
nHA | 3 | APOL | 58.477 |
nHD | 1 | BPOL | 36.713 |
QED | 0.456 |
Synth | 4.248 |
Natural Product Likeliness | 2.773 |
NR-PPAR-gamma | 0.043 |
Lipinski | Accepted |
Pfizer | Rejected |
GSK | Rejected |
Golden Triangle | Accepted |
Pgp-inh | 0.948 |
Pgp-sub | 0.005 |
HIA | 0.015 |
CACO-2 | -4.495 |
MDCK | 0.0000209 |
BBB | 0.808 |
PPB | 0.951932 |
VDSS | 1.521 |
FU | 0.0781152 |
CYP1A2-inh | 0.09 |
CYP1A2-sub | 0.214 |
CYP2c19-inh | 0.725 |
CYP2c19-sub | 0.846 |
CYP2c9-inh | 0.362 |
CYP2c9-sub | 0.451 |
CYP2d6-inh | 0.053 |
CYP2d6-sub | 0.072 |
CYP3a4-inh | 0.896 |
CYP3a4-sub | 0.463 |
CL | 8.208 |
T12 | 0.149 |
hERG | 0.006 |
Ames | 0.018 |
ROA | 0.008 |
SkinSen | 0.673 |
Carcinogencity | 0.076 |
EI | 0.068 |
Respiratory | 0.035 |
NR-Aromatase | 0.036 |
Antiviral | Yes |
Prediction | 0.540146 |